Recent drug approvals for NSCLC

Eric K. Singhi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of recent drug approvals for non-small cell lung cancer (NSCLC). In the past few years, there has been significant progress in the development of drugs for both early-stage and advanced NSCLC. In particular, adjuvant therapy with atezolizumab and osimertinib and novel targeted therapies have considerably improved patient outcomes. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.